Novo Nordisk

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Novo Nordisk's Wegovy pill ad 'misleading', says FDA

Novo Nordisk has been criticised by the FDA for a TV ad for the Wegovy pill, which the agency claims makes "false and misleading" claims.

News

Kailera, Hengrui stake claim to oral weight loss category

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

Black and white image of a white flag of surrender

Novo Nordisk rises as Hims & Hers backs down on oral GLP-1

Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

News

Hims & Hers copies Novo Nordisk's new Wegovy pill

Competition has already arrived for Novo Nordisk's Wegovy pill, as telehealth company Hims & Hers launches a compounded version.

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk's Wegovy pill ad 'misleading', says FDA

Kailera, Hengrui stake claim to oral weight loss category

Novo Nordisk rises as Hims & Hers backs down on oral GLP-1

Four reasons pharma is sweeping the Super Bowl despite FDA f...

Hims & Hers copies Novo Nordisk's new Wegovy pill

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Novo Nordisk

Editor's Picks